Gupta AK, Teasell EM, Economopoulos V, Mirmirani P
SURMOUNT OSA demonstrated after 52 weeks of treatment, participants who received tirzepatide had greater likelihood of remission or improvement to mild OSA as well as reduced apnea-hypopnea index (AHI) values, hypoxic burden, and systolic blood pressure
8 SUMMIT also demonstrated significant improvements in patient-reported outcomes: at 52 weeks, tirzepatide increased KCCQ-CSS, with a between-group mean difference of 6.9 points, and increased 6-minute walk distance, with a between-group mean difference of 18.3 m
And leading that charge
Incline Peps does not present Reta as a treatment, prescription product, medicine, supplement, cosmetic product or personal-use alternative to any licensed product
Mark Gordon (USA) featured on The Joe Rogan Experience (4 appearances) for his work in hormones & brain health